Success Metrics

Clinical Success Rate
28.6%

Based on 2 completed trials

Completion Rate
29%(2/7)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
5(63%)

Phase Distribution

Ph phase_1
8
100%

Phase Distribution

8

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
8(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

25.0%

2 of 8 finished

Non-Completion Rate

75.0%

6 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(2)
Terminated(6)

Detailed Status

Terminated5
Completed2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
28.6%
Most Advanced
Phase 1

Trials by Phase

Phase 18 (100.0%)

Trials by Status

completed225%
withdrawn113%
terminated563%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_1

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

NCT01881789
terminatedphase_1

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

NCT01416428
terminatedphase_1

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

NCT01999335
terminatedphase_1

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

NCT02244112
terminatedphase_1

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01832727
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01881789Phase 1

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Terminated
NCT01416428Phase 1

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Terminated
NCT01999335Phase 1

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Terminated
NCT02244112Phase 1

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Terminated
NCT01832727Phase 1

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Terminated
NCT02227914Phase 1

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Withdrawn
NCT01129349Phase 1

Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

Completed
NCT02072863Phase 1

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8